Gemcitabin, Cisplatin and Durvalumab

Phase 2Monoclonal antibody

IInsel Gruppe AG, University Hospital Bern

Gemcitabin, Cisplatin and Durvalumab is one of 38 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary Tract CancerActive, not recruiting

Biliary Tract CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

208 competitors in Biliary Tract Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

34 2

Imfinzi

AstraZeneca

Phase 3

26 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

32 4

Eloxatin

Teva

Phase 3

13 5

Keytruda

Merck & Co.

Phase 3

10 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

18 7

Adrucil

EElorac, Inc.

Phase 3

4 8

Herceptin

OOrganon and Co

Phase 3

4 9

Camptosar

EEastern Cooperative Oncology Group

Phase 3

3 10

Navmi

SSummit Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Biliary Tract Cancer

NCT06274879

Clinical

Trials by Indication[1]

Biliary Tract Cancer1 trial

Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer

Not yet recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06274879·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gemcitabin, Cisplatin and Durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemcitabin, Cisplatin and Durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemcitabin, Cisplatin and Durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insel Gruppe AG, University Hospital Bern company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: IInsel Gruppe AG, University Hospital Bern

Gemcitabin, Cisplatin and Durvalumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News